•  
  •  
 

Subject Area

Clinical Pathology

Article Type

Original Study

Abstract

Objective The objective of this study was to add to the scope of the role of vascular endothelial growth factor (VEGF) +936C/T gene polymorphism in the prognosis of B-cell chronic lymphocytic leukemia (CLL) in Egyptian patients. Background CLL is a common lymphoid malignancy that has a highly variable clinical course. Several studies have targeted to determine the high risk of disease progression; VEGF-mediated angiogenesis is one of the most vital regulators of angiogenesis and vascular permeability, which can contribute to the pathogenesis of B-CLL. Patients and methods This prospective case–control study was conducted on 30 patients of CLL and 20 age-matched and sex-matched healthy individuals as a control group from January 2016 to January 2018. All patients were subjected to full history taking, clinical examination, and laboratory investigations. Genotyping of VEGF + 936C/T (rs3025039) single nucleotide polymorphism was done using PCR-restriction fragment length polymorphism method. Results VEGF + 936C/T gene polymorphism showed no statistically significant differences in the distribution of the genotypes and allele frequencies between patients and controls. No significant relation was found between genotype distribution and sex, age, somatic hypermutation, hemoglobin, total leukocytic count, and absolute lymphocytes; however, TT genotype and recessive genetic model (CT + CC) revealed a significant relationship with the platelet count in patients with CLL (P = 0.014). A statistically significant relationship was depicted between TT genotype and recessive genetic model (CT + CC) and poor prognostic markers such as lactate dehydrogenase, β2 microglobulin, and modified Rai staging system (IV). Conclusion VEGF + 936C/T gene polymorphism can predict poor prognosis in patients with CLL.

Download

Share

COinS